Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention

被引:106
作者
DeFronzo, Ralph A. [1 ]
Abdul-Ghani, Muhammad [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA
关键词
IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; LIFE-STYLE INTERVENTION; CLAUDE-BERNARD-LECTURE; INSULIN-RESISTANCE; FASTING GLUCOSE; PLASMA-GLUCOSE; FOLLOW-UP; HIGH-RISK; METFORMIN;
D O I
10.2337/dc11-s221
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the U.S., similar to 21 X 10(6) individuals have type 2 diabetes, and twice as many have impaired glucose tolerance (IGT). Approximately 40-50% of individuals with IGT will progress to type 2 diabetes over their lifetime. Therefore, treatment of high-risk individuals with IGT to prevent type 2 diabetes has important medical, economic, social, and human implications. Weight loss, although effective in reducing the conversion of IGT to type 2 diabetes, is difficult to achieve and maintain. Moreover, 40-50% of IGT subjects progress to type 2 diabetes despite successful weight reduction. In contrast, pharmacological treatment of IGT with oral antidiabetic agents that improve insulin sensitivity and preserve beta-cell function-the characteristic pathophysiological abnormalities present in IGT and type 2 diabetes-uniformly have been shown to prevent progression of IGT to type 2 diabetes. The most consistent results have been observed with the thiazolidinediones (Troglitazone in the Prevention of Diabetes [TRIPOD], Pioglitazone in the Prevention of Diabetes [PIPOD], Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication [DREAM], and Actos Now for the Prevention of Diabetes [ACT NOW]), with a 50-70% reduction in IGT conversion to diabetes. Metformin in the U.S. Diabetes Prevention Program (DPP) reduced the development of type 2 diabetes by 31% and has been recommended by the American Diabetes Association (ADA) for treating high-risk individuals with IGT. The glucagon-like peptide-1 analogs, which augment insulin secretion, preserve beta-cell function, and promote weight loss, also would be expected to be efficacious in preventing the progression of IGT to type 2 diabetes. Because individuals in the upper tertile of IGT are maximally/near-maximally insulin resistant, have lost 70-80% of their beta-cell function, and have an similar to 10% incidence of diabetic retinopathy, pharmacological intervention, in combination with diet plus exercise, should be instituted.
引用
收藏
页码:S202 / S209
页数:8
相关论文
共 60 条
[1]   Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose [J].
Abdul-Ghani, MA ;
Tripathy, D ;
DeFronzo, RA .
DIABETES CARE, 2006, 29 (05) :1130-1139
[2]   Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance - Results from the veterans administration genetic epidemiology study [J].
Abdul-Ghani, MA ;
Jenkinson, CP ;
Richardson, DK ;
Tripathy, D ;
DeFronzo, RA .
DIABETES, 2006, 55 (05) :1430-1435
[3]   One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes [J].
Abdul-Ghani, Muhammad A. ;
Abdul-Ghani, Tamam ;
Ali, Nibal ;
DeFronzo, Ralph A. .
DIABETES CARE, 2008, 31 (08) :1650-1655
[4]   Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose [J].
Abdul-Ghani, Muhammad A. ;
Williams, Ken ;
DeFronzo, Ralph ;
Stern, Michael .
DIABETES CARE, 2006, 29 (07) :1613-1618
[5]   Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes [J].
Abdul-Ghani, Muhammad A. ;
DeFronzo, Ralph A. .
DIABETES CARE, 2009, 32 :S194-S198
[6]  
[Anonymous], NAT DIAB FACT SHEET
[7]  
[Anonymous], EXP REV ENDOCIRNOL M
[8]  
[Anonymous], J CLIN ENDO IN PRESS
[9]   Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].
Astrup, Arne ;
Rossner, Stephan ;
Van Gaal, Luc ;
Rissanen, Aila ;
Niskanen, Leo ;
Al Hakim, Mazin ;
Madsen, Jesper ;
Rasmussen, Mads F. ;
Lean, Michael E. J. .
LANCET, 2009, 374 (9701) :1606-1616
[10]   The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes [J].
Bergman, RN ;
Finegood, DT ;
Kahn, SE .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :35-45